Streetbeat News

Regulatory

BTCUSD

Countries worldwide are investing in blockchain technology and cryptocurrency, with Singapore, Switzerland, South Korea, Malta, the U.S., and UAE leading the way. Singapore recently received a Major Payment Institution license, enabling it to offer Digital Payment Token services. South Korea disclosed $98.5 billion in foreign cryptocurrency assets. The U.S. leads in blockchain innovations and venture capital investments. The UAE is exploring blockchain technology across various industries. The global blockchain tech market is expected to reach $1.432 billion by 2030, and the global Fintech Blockchain Market is projected to expand to $21.67 billion by 2028.

Portfolio Pulse from Khyathi Dalal

October 03, 2023 | 7:14 pm

MKUL

Trading of Molekule Group's shares has been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 7:02 pm

FEMY

Femasys Inc. (NASDAQ:FEMY) shares traded lower on Tuesday, following a period of volatility since the company received FDA 510(k) clearance for FemaSeed, an infertility treatment, in late September. Despite a price target increase from HC Wainwright & Co. last Friday, Femasys shares fell by nearly 40% on Tuesday. The company also announced the successful completion of the annual Medical Device Single Audit Program (MDSAP) surveillance audit with no nonconformances and no findings.

Portfolio Pulse from Ryan Gustafson

October 03, 2023 | 6:56 pm

CYBN

Cybin Inc. (NYSE:CYBN) has completed dosing of the final participant cohort in the Phase 2 study on its deuterated psilocybin analog CYB003 for Major Depressive Disorder (MDD) treatment. The company expects to provide topline efficacy data before the end of the year. Cybin will now focus on the upcoming data submission to the FDA toward a potential scaling to a Phase 3 pivotal study in early 2024. The Phase 1/2 study evaluated CYB003’s safety, tolerability, PK/PD and psychedelic effect in ascending oral doses in both participants with MDD and healthy volunteers.

Portfolio Pulse from Lara Goldstein

October 03, 2023 | 6:51 pm

NVAX

The FDA has granted Emergency Use Authorization for Novavax's COVID-19 vaccine, Adjuvanted (2023-2024 Formula), for individuals aged 12 and older. This has led to an increase in Novavax's share price.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 6:49 pm

NVAX

SPY

The FDA has authorized the use of Novavax's Covid-19 vaccine, which has been updated to include the spike protein from the SARS-COV-2 Omicron variant lineage Xbb.1.5, in individuals aged 12 and older.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 6:44 pm

NVAX

SPY

The FDA has amended the Emergency Use Authorization of Novavax's Covid-19 vaccine to include the 2023-2024 formula. However, the vaccine is no longer authorized for use in the U.S.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 6:43 pm

NVAX

NovaVax anticipates that the U.S. Centers for Disease Control and Prevention (CDC) will soon issue updated recommendations for the use of its vaccine.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 6:42 pm

NVAX

The U.S. FDA has authorized the first and only protein-based non-mRNA updated Covid-19 vaccine for use in people aged 12 years and older. The vaccine is likely produced by Novavax (NVAX).

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 6:41 pm

BTCUSD

CELUSD

ETHUSD

The potential successor to the defunct cryptocurrency lender, Celsius (CRYPTO: CEL), plans to restart the business with an initial funding of up to $450 million in cryptocurrency, pending court approval. The entity, temporarily named NewCo, aims to commence reimbursement to clients with assets locked following Celsius's downfall in June 2022. The investment group Fahrenheit will oversee NewCo's operations and has pledged an investment of up to $50 million for an equity position in the venture. NewCo also plans to be publicly traded on the Nasdaq.

Portfolio Pulse from Murtuza Merchant

October 03, 2023 | 6:37 pm